EMVision unveils stroke diagnosis device ahead of planned 2023 commercial release

Medical device company EMVision has announced a new version of its brain scanner, which it aims to make commercially available in 2023.

EMVision is a University of Queensland spinout based on over a decade of R&D, and listed on the ASX in late-2018. 

The company’s portable scanner is “targeted for use in intensive care units, stroke and neurology wards, angiogram suites, cardiology wards, emergency departments as well as rural and remote locations,” the company said in a statement on Tuesday.

It is an alternative to CT and MRI scans, and according to the company can diagnose a stroke within minutes, fast-tracking intervention in the critical “golden hour” after the event.

Over 445,000 Australians deal with the effects of stroke, with this predicted to nearly double by 2050 without action.

“We are tackling the immense health burden that is stroke first, with potential adjacencies in traumatic brain injury and other neurological disorders. We see an enormous market opportunity ahead poised for disruption,” said CEO Dr Ron Weinberger. 

“Our device will undergo various tests as we prepare for our next stage of expanded clinical studies.”

Initial clinical trials were announced in early 2020.  

According to the Australian Financial Review, EMVision has so far run a 30-patient pilot study

The company says their device — compared in size to an ultrasound trolley — can rapidly distinguish between ischaemic (blockage) and haemorrhagic (bleed) strokes using artificial intelligence.

Picture: EMVision

Subscribe to our free @AuManufacturing newsletter here.